U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07586306) titled 'A Safety Study of Contralateral Eye Dosing of VGR-R01 in Participants With Bietti's Crystalline Dystrophy (BCD)' on April 23.
Brief Summary: This is a multi-centre, single- arm, non-randomized, open-label phase 1/2 clinical trial which enables dosing of the fellow eyes of patients who received VGR-R01 administration in previous studies.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Bietti Crystalline Dystrophy
Intervention:
BIOLOGICAL: VGR-R01
CYP4v2-coding gene delivered by AAV vector
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Vitalgen BioPharma Co., Ltd.
Published by HT Digital Content Serv...